Pakistan Journal of Biological Sciences1028-88801812-5735Asian Network for Scientific Information10.3923/pjbs.2007.4246.4250 p16/CDKN2A Gene in Malignant Gliomas of Iranian Patients]]>ZadehMohammad DilmaghaniAminiReza FiroozrayMohsen Derakhshandeh-PeykarPupak 1220071023Homozygous deletion is the main mechanism of CDKN2A gene inactivation in malignant gliomas. However different frequencies were reported for its deletion. In order to find the homozygous deletion frequency among Iranian patients, we have analyzed the status of CDKN2A gene in 40 malignant gliomas and examined their 1α and 2 exons by comparative multiplex Polymerase Chain Reaction (PCR), using D9S171 chromosomal marker as an internal control. We found homozygous deletion in 6 out of 7 cases (85.7%) of anaplastic astrocytomas and 20 out of 33 cases (60.6%) of glioblastoma multiforme, in total 26 out of 40 cases (65%) of malignant gliomas. We also found that CDKN2A deleted patients were younger than CDKN2A non-deleted patients and that exon 2 was deleted more than exon 1α.]]>Barker, F.G., P. Chen, F. Furman, K.D. Aldape, M.S. Edwards and M.A. Israel,1997p16 deletion and mutation analysis in human brain tumors.]]>31723Biernat, W., Y. Tohma, Y. Yonekawa, P. Kleihues and H. Ohgaki,1997de novo) and secondary glioblastomas.]]>94303309Bigner, S.H., J. Mark, P.C. Burger, M.S. Jr. Mahaley, D.E. Bullard and L.H. Muhlbaier, D.D. Bigner,198848405411Goldstein, A.M.,2004CDKN2A mutations.]]>23630630Zhai, G. and X. Yuan,1998p16 gene in the progression of brain astrocytomas.]]>10284287Ichimura, K., M.B. Bolin, H.M. Goike, E.E. Schmidt, A. Moshref and V.P. Collins,200060417424Kamiryo, T., K. Tada, S. Shiraishi, N. Shinojima and H. Nakamaura et al.,2002p16 gene and correlation with survival in patients with glioblastoma multiforme.]]>96815822Kraus, J.A., N. Glesmann, M. Beck, D. Krex, T. Klockgether, G. Schackert and U. Schlegel,2000CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.]]>488994Louis, D.N., H. Ohgaki, O.D. Wiestler, W.K. Cavenee and P.C. Burger et al.,200711497109Maher, E.A., F.B. Furnari, R.M. Bachoo, D.H. Rowitch, D.N. Louis and W.K. Cavenee, R.A. DePinho,20011513111333Zadeh, M.D., R. Amini, M. Firoozray and P. Derakhshandeh-Peykar,2007p16/CDKN2A gene in malignant gliomas of Iranian patients.]]>1042464250Nakamura, M., T. Watanabe, U. Klangby, C. Asker and K. Wiman et al.,2001ARF deletion and methylation in genetic pathways to glioblastomas.]]>11159168Nobori, T., K. Miura, D.J. Wu, A. Lois, K. Takabayashi and D.A. Carson,1994368753756Ohgaki, H., P. Dessen, B. Jourde, S. Horstmann and T. Nishikawa et al.,20046468926899Ohgaki, H.,20052517Olopade, O.I., R.B. Jenkins, D.T. Ransom, K. Malik and H. Pomykala et al.,19925225232529Rocco, J.W. and D. Sidransky,20012644255Shi, S.R., R.J. Cote, L. Wu, C. Liu and R. Datar et al.,20025010051011Tachibana, I., J.S. Smith, K. Sato, S.M. Hosek, D.W. Kimmel and R.B. Jenkins,2000INK4Ap14ARF and CDK4 alterations in familial glioma.]]>92136141Vermeulen, K., D.R. van Bockstaele and Z.N. Berneman,200336131149Wang, T.J., M.S. Huang, C.Y. Hong, V. Tse, G.D. Silverberg and M. Hsiao,2001p53, p21 and p16 gene therapy effects on glioblastoma tumorigenicity in situ.]]>287173180Wrensch, M., Y. Minn, T. Chew, M. Bondy and M.S. Berger,20024278299Xing, E.P., Y. Nie, L.D. Wang, G.Y. Yang and C.S. Yang,1999INK4A and deletion of p15INK4B are frequent events in human esophageal cancer in Linxian, China.]]>207784